Global Human Chorionic Gonadotropin Market is having an exponential growth rate of 7.5% from 2022 to 2030.
Fertility patterns worldwide have changed dramatically and a rise in infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.
Human chorionic gonadotropin (HCG) is available in two forms. One is a powder derived from the urine of pregnant women which needs to be dissolved in sterile water, loaded into a syringe, and injected into a muscle. Ovidrel is another more expensive but more convenient product produced by recombinant technology, pre-packaged into a syringe for injection with a short needle. HCG is used in some patients who are usually receiving other fertility drugs in order to trigger ovulation. The eggs are released from their follicles about 40 hours after the HCG injection. Artificial insemination will usually be scheduled for 36-44 hours after the HCG injection when a single insemination is planned or at approximately 24 and 48 hours after the HCG injection when two inseminations are to be done.
Two main regimens of gonadotropin ovarian stimulation are used, namely step-up and the step-down protocols. The choice of gonadotropin preparation and treatment regimen depends on the underlying ovarian dysfunction. Strict monitoring of gonadotropin treatment with implementation of strict cancellation criteria are recommended to minimize the risks of ovarian hyperstimulation and multiple pregnancy.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Fertility patterns worldwide have changed dramatically and a rise in infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.
Human chorionic gonadotropin (HCG) is available in two forms. One is a powder derived from the urine of pregnant women which needs to be dissolved in sterile water, loaded into a syringe, and injected into a muscle. Ovidrel is another more expensive but more convenient product produced by recombinant technology, pre-packaged into a syringe for injection with a short needle. HCG is used in some patients who are usually receiving other fertility drugs in order to trigger ovulation. The eggs are released from their follicles about 40 hours after the HCG injection. Artificial insemination will usually be scheduled for 36-44 hours after the HCG injection when a single insemination is planned or at approximately 24 and 48 hours after the HCG injection when two inseminations are to be done.
Two main regimens of gonadotropin ovarian stimulation are used, namely step-up and the step-down protocols. The choice of gonadotropin preparation and treatment regimen depends on the underlying ovarian dysfunction. Strict monitoring of gonadotropin treatment with implementation of strict cancellation criteria are recommended to minimize the risks of ovarian hyperstimulation and multiple pregnancy.
Oligospermia supported the demand for HCG drugs in the market
For the purpose of this study, the global human chorionic gonadotropin market is represented by key therapeutic areas such as female infertility treatment, oligospermia, cryptorchidism and others. Several factors such as growing incidence of infertility in women, contributed by increased maternity age, lifestyle effects and others, hormonal dysfunctions in men and growing incidence of oligospermia are the key factors that have supported the demand for HCG drugs in the market.Recombinant HCG is Key driving factor
For the purpose of this report, the technology segment of the global human chorionic gonadotropin market has been segmented into natural source extract and recombinant DNA technology. Urine-derived HCG has been a chief treatment source for various hormonal conditions. However in view of purity-related issues, HCG manufacturing through recombinant production technology. Equal efficacy or recombinant HCG along with added safety as against natural source HCG are the key driving factors that lead to higher demand for recombinant HCG in the global market.Asia-Pacific is expected to be the most potential regional market
North America is expected to be the largest and most potential regional market for human chorionic gonadotropin. North America constitutes regional markets of U.S. and Canada, the rising incidence of infertility cases, lifestyle effects, and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin market. Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by 2030. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape, increasing disposable incomes, growing public awareness related to infertility therapy, and increasing government support through providing favorable policies are the major factors expected to assist the growth of Asia-Pacific market.Market Players
The leading key players in human chorionic gonadotropin market are EMD Serono, Inc., Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius Kabi USA, LLC.Historical & Forecast Period
This report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Human Chorionic Gonadotropin market are as follows:- Research and development budgets of manufacturers and government spending.
- Revenues of key companies in the market segment.
- Number of end users and consumption volume, price and value.
- Geographical revenues generated by countries considered in the report.
- Micro and macro environment factors that are currently influencing the Human Chorionic Gonadotropin market and their expected impact during the forecast period.
- The market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Treatment
- Female Infertility Treatment
- Oligospermia Treatment
- Cryptorchidism Treatment
- Others
Technology
- Natural Source Extraction
- Recombinant DNA Technology
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Human Chorionic Gonadotropin market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Human Chorionic Gonadotropin market?
- Which is the largest regional market for Human Chorionic Gonadotropin market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Human Chorionic Gonadotropin market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Human Chorionic Gonadotropin market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Human Chorionic Gonadotropin Market
2.2. Global Human Chorionic Gonadotropin Market, by Treatment, 2021 (US$ Million)
2.3. Global Human Chorionic Gonadotropin Market, by Technology, 2021 (US$ Million)
2.4. Global Human Chorionic Gonadotropin Market, by Geography, 2021 (US$ Million)
2.5. Impact of COVID-19
2.6. Attractive Investment Proposition by Geography, 2021
2.7. Competitive Analysis
2.7.1. Market Positioning of Key Human Chorionic Gonadotropin Market Vendors
2.7.2. Strategies Adopted by Human Chorionic Gonadotropin Market Vendors
2.7.3. Key Industry Strategies
3. Human Chorionic Gonadotropin Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Human Chorionic Gonadotropin Market Value, 2020-2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat of Substitutes
3.6.4. Threat of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
4. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Female Infertility Treatment
4.3.2. Oligospermia Treatment
4.3.3. Cryptorchidism Treatment
4.3.4. Others
5. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Natural Source Extraction
5.3.2. Recombinant DNA Technology
6. North America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
6.3. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
6.4. Human Chorionic Gonadotropin Market: by Region, 2020-2030, USD (Million)
6.4.1. North America
6.4.1.1. U.S.
6.4.1.2. Canada
6.4.1.3. Rest of North America
7. UK and European Union Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
7.3. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
7.4. Human Chorionic Gonadotropin Market: by Region, 2020-2030, USD (Million)
7.4.1. UK and European Union
7.4.1.1. UK
7.4.1.2. Germany
7.4.1.3. Spain
7.4.1.4. Italy
7.4.1.5. France
7.4.1.6. Rest of Europe
8. Asia Pacific Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
8.3. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
8.4. Human Chorionic Gonadotropin Market: by Region, 2020-2030, USD (Million)
8.4.1. Asia Pacific
8.4.1.1. China
8.4.1.2. Japan
8.4.1.3. India
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Rest of Asia Pacific
9. Latin America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
9.3. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
9.4. Human Chorionic Gonadotropin Market: by Region, 2020-2030, USD (Million)
9.4.1. Latin America
9.4.1.1. Brazil
9.4.1.2. Mexico
9.4.1.3. Rest of Latin America
10. Middle East and Africa Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Human Chorionic Gonadotropin Market: by Treatment, 2020-2030, USD (Million)
10.3. Human Chorionic Gonadotropin Market: by Technology, 2020-2030, USD (Million)
10.4. Human Chorionic Gonadotropin Market: by Region, 2020-2030, USD (Million)
10.4.1. Middle East and Africa
10.4.1.1. GCC
10.4.1.2. Africa
10.4.1.3. Rest of Middle East and Africa
11. Company Profiles
11.1. Ferring B.V.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. EMD Serono, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Fresenius Kabi USA, LLC
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Merck & Co., Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic InitiativesList of Figures
Figure 1. Global Human Chorionic Gonadotropin Market: Market Coverage
Figure 2. Research Methodology and Data Sources
Figure 3. Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4. Global Human Chorionic Gonadotropin Market: Quality Assurance
Figure 5. Global Human Chorionic Gonadotropin Market, By Treatment, 2021
Figure 6. Global Human Chorionic Gonadotropin Market, By Technology, 2021
Figure 7. Global Human Chorionic Gonadotropin Market, By Geography, 2021
Figure 8. Global Human Chorionic Gonadotropin Market, By Treatment, 2021 vs 2030, %
Figure 9. Global Human Chorionic Gonadotropin Market, By Technology, 2021 vs 2030, %
Figure 10. U.S. Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 11. Canada Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 12. Rest of North America Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 13. UK Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 14. Germany Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 15. Spain Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 16. Italy Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 17. France Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 18. Rest of Europe Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 19. China Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 20. Japan Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 21. India Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 22. Australia Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 23. South Korea Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 24. Rest of Asia Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 25. Brazil Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 26. Mexico Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 27. Rest of Latin America Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 28. GCC Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 29. Africa Human Chorionic Gonadotropin Market (US$ Million), 2020-2030
Figure 30. Rest of Middle East and Africa Human Chorionic Gonadotropin Market (US$ Million), 2020-2030List of Tables
Table 1 Global Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 2 Global Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Table 3 North America Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 4 North America Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Table 5 UK and European Union Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 6 UK and European Union Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Table 7 Asia Pacific Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 8 Asia Pacific Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Table 9 Latin America Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 10 Latin America Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Table 11 Middle East and Africa Human Chorionic Gonadotropin Market by Treatment, 2020-2030, USD (Million)
Table 12 Middle East and Africa Human Chorionic Gonadotropin Market by Technology, 2020-2030, USD (Million)
Companies Mentioned
- Ferring B.V.
- Bristol-Myers Squibb Company
- EMD Serono Ltd.
- Fresenius Kabi USA LLC
- Merck & Co. Ltd.
